gms | German Medical Science

102. Jahrestagung der DOG

Deutsche Ophthalmologische Gesellschaft e. V.

23. bis 26.09.2004, Berlin

What are the current therapeutic options to treat corneal neovascularization?

Meeting Abstract

Search Medline for

  • corresponding author F. E. Kruse - Augenklinik mit Poliklinik, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen
  • C. Cursiefen - Augenklinik mit Poliklinik, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen

Evidenzbasierte Medizin - Anspruch und Wirklichkeit. 102. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft. Berlin, 23.-26.09.2004. Düsseldorf, Köln: German Medical Science; 2004. Doc04dogSA.14.05

The electronic version of this article is the complete one and can be found online at:

Published: September 22, 2004

© 2004 Kruse et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.




To provide an up to-date review on the current therapeutic options against corneal neovascularization.


A comprehensive literature search was performed for antiangiogenic therapeutic strategies available at the cornea. Therapeutic options were divided into angiostatic, angioregressive and angioocclusive approaches.


Angiostatic options include indirect antiangiogenic agents such as topical steroids or cyclosporine A and also novel direct antiangiogenic agents. The latter are now mainly in phase 2 and 3 clinical trials for cancer and AMD patients (VEGF Trap, Macugen etc.). Angioregressive strategies have not yet left the preclinical experimental state, but could e.g. be based on a combination of a TIE 2 receptor agonist and VEGF blockade. Angioocclusive therapies include cautery of established large vessels or photodynamic therapy at the cornea.


A wide array of novel angiostatic (pharmacologic) agents will be available in the near future, either topically or as a systemic formulation, to treat corneal neovascularization.